Mapk/erk kinase inhibitorsCompounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of : wherein the variables are as defined herein.The compound that has following formula:whereinq is selected from cr 7r 8, co and cs; r 1be selected from (c 3-12) cycloalkyl, assorted (c 3-12) cycloalkyl, (c 9-12) bicyclic alkyl, assorted (c 3-12) bicyclic alkyl, (c 4-12) aryl, assorted (c 1-10) aryl, (c 9-12) aryl bicyclic and assorted (c 4-12) aryl bicyclic, be substituted separately or be not substituted; r 2be hydrogen or the substituting group that can be transformed into hydrogen in vivo; r 3be selected from amino, (c 1-10) alkylamino, alkoxy amino, sulfonamido, imino-, alkylsulfonyl, sulfinyl, (c 2-10) alkyl, halo (c 1-10) alkyl, carbonyl (c 1-3) alkyl, thiocarbonyl (c 1-3) alkyl, (c 1-6) oxa alkyl, (c 1-4) oxygen base alkyl (c 1-4) oxa alkyl, alkylsulfonyl (c 1-3) alkyl, sulfinyl (c 1-3) alkyl, amino (c 1-10) alkyl, imino-(c 1-3) alkyl, (c 3-12) cycloalkyl (c 1-5) alkyl, assorted (c 3-12) cycloalkyl (c 1-5) alkyl, aryl (c 1-10) alkyl, heteroaryl (c 1-5) alkyl, (c 9-12) aryl bicyclic (c 1-5) alkyl, assorted (c 8-12) aryl bicyclic (c 1-5) alkyl, (c 3-12) cycloalkyl, assorted (c 3-12) cycloalkyl, (c 9-12) bicyclic alkyl, assorted (c 3-12) bicyclic alkyl, (c 4-12) aryl, assorted (c 1-10) aryl, (c 9-12) aryl bicyclic and assorted (c 4-12) aryl bicyclic, be substituted separately or be not substituted; r 4and r 5be selected from hydrogen, oxygen base, hydroxyl, ketonic oxygen base, alkoxyl group, aryloxy, heteroaryloxy, carbonyl, oxygen base carbonyl, amino, (c independently of one another 1-10) alkylamino, sulfonamido, imino-, alkylsulfonyl, sulfinyl, (c 1-10) alkyl, halo (c 1-10) alkyl, carbonyl (c 1-3) alkyl, thiocarbonyl (c 1-3) alkyl, alkylsulfonyl (c 1-3) alkyl, sulfinyl (c 1-3) alkyl, amino (c 1-10) alkyl, imino-(c 1-3) alkyl, (c 3-12) cycloalkyl (c 1-5) alkyl, assorted (c 3-12) cycloalkyl (c 1-5) alkyl, aryl (c 1-10) alkyl, heteroaryl (c 1-5) alkyl, (c 9-12) aryl bicyclic (c 1-5) alkyl, assorted (c 8-12) aryl bicyclic (c 1-5) alkyl, (c 3-12) cycloalkyl, assorted (c 3-12) cycloalkyl, (c 9-12) bicyclic alkyl, assorted (c 3-12) bicyclic alkyl, (c 4-12) aryl, assorted (c 1-10) aryl, (c 9-12) aryl bicyclic and assorted (c 4-12) aryl bicyclic, being substituted separately or not being substituted, condition is r 4and r 5the atom that connects at their does not exist when forming the part of two keys independently of one another; r 6be selected from hydrogen, heteroaryloxy, amino, (c 1-10) alkylamino, sulfonamido, imino-, alkylsulfonyl, sulfinyl, (c 1-10) alkyl, halo (c 1-10) alkyl, carbonyl (c 1-3) alkyl, thiocarbonyl (c 1-3) alkyl, alkylsulfonyl (c 1-3) alkyl, sulfinyl (c 1-3) alkyl, amino (c 1-10) alkyl, imino-(c 1-3) alkyl, (c 3-12) cycloalkyl (c 1-5) alkyl, assorted (c 3-12) cycloalkyl (c 1-5) alkyl, aryl (c 1-10) alkyl, heteroaryl (c 1-5) alkyl, (c 9-12) aryl bicyclic (c 1-5) alkyl, assorted (c 8-12) aryl bicyclic (c 1-5) alkyl, (c 3-12) cycloalkyl, assorted (c 3-12) cycloalkyl, (c 4-12) aryl and assorted (c 1-10) aryl, being substituted separately or not being substituted, condition is r 6the atom that connects at its does not exist when forming the part of two keys; with r 7and r 8be selected from hydrogen, cyano group, heteroaryloxy, carbonyl, oxygen base carbonyl, aminocarboxyl, amino, (c independently of one another 1-10) alkylamino, sulfonamido, imino-, alkylsulfonyl, sulfinyl, (c 1-10) alkyl, halo (c 1-10) alkyl, carbonyl (c 1-3) alkyl, thiocarbonyl (c 1-3) alkyl, alkylsulfonyl (c 1-3) alkyl, sulfinyl (c 1-3) alkyl, amino (c 1-10) alkyl, imino-(c 1-3) alkyl, (c 3-12) cycloalkyl (c 1-5) alkyl, assorted (c 3-12) cycloalkyl (c 1-5) alkyl, aryl (c 1-10) alkyl, heteroaryl (c 1-5) alkyl, (c 9-12) aryl bicyclic (c 1-5) alkyl, assorted (c 8-12) aryl bicyclic (c 1-5) alkyl, (c 3-12) cycloalkyl, assorted (c 3-12) cycloalkyl, (c 9-12) bicyclic alkyl, assorted (c 3-12) bicyclic alkyl, (c 4-12) aryl, assorted (c 1-10) aryl, (c 9-12) aryl bicyclic and assorted (c 4-12) aryl bicyclic, be substituted separately or be not substituted, perhaps r 7and r 5form replacement or unsubstituted ring together, condition is r 8the atom that connects at its does not exist when forming the part of two keys, condition is:(a) work as r 6do not exist, q is co, r 1be unsubstituted phenyl and r 2when being hydrogen, r then 3be not-ch 2cn; (b) work as r 6do not exist, q is co, r 1be tetrahydrochysene-2h-pyrans-3,4,5-three basic triacetate and r 2when being hydrogen, r then 3be not-ch 2cl; (c) work as r 6do not exist, q is co, r 1be 2,2,6,6-tetramethyl piperidine-1-alcohol and r 2when being hydrogen, r then 3be not-ch=ch-ph; with (d) work as r 6do not exist, q is co, r 1be substituted or unsubstituted phenyl, r 2be hydrogen and r 4and r 5when being hydrogen or methyl independently of one another, r then 3be not-nh-r 10, r wherein 10be pyridine-2-base or be substituted or unsubstituted phenyl.
ＭＡＰＫ／ＥＲＫ 키나아제 억제제 다음에서 선택된 화합물을 포함하는 MEK에 대해 사용가능한 화합물, 의약 조성물, 및 방법이 제공된다:  식 중, 치환기들은 본문에 정의된 바와 같다.다음 화학식을 갖는 화합물 및 약학적으로 허용가능한 이의 염: [이미지] 식 중, R1은 (C4-12)아릴 및 헤테로(C1-10)아릴로 이루어진 군 중에서 선택된 것으로, 이들 각각은 치환되거나 치환되지 않은 것이다; R2은 수소; R4 및 R5 는 각각 수소 및 치환되거나 치환되지 않은 (C1-5) 알킬로 이루어진 군 중에서 독립적으로 선택된다; R9은 수소이고; R11은 수소, (C1-10)알킬, 할로(C1-10)알킬, 카보닐(C1-3)알킬, 티오카보닐(C1-3)알킬, 설포닐(C1-3)알킬, 설피닐(C1-3)알킬, 아미노(C1-10)알킬, 이미노(C1-3)알킬, (C3-12)사이클로알킬(C1-5)알킬, 헤테로(C3-12)사이클로알킬(C1-5)알킬, 아릴(C1-10)알킬, 헤테로아릴(C1-5)알킬, (C9-12)바이사이클로아릴(C1-5)알킬, 헤테로(C8-12)바이사이클로아릴(C1-5)알킬, (C3-12)사이클로알킬, 헤테로(C3-12)사이클로알킬, (C9-12)바이사이클로알킬, 헤테로(C3-12)바이사이클로알킬, (C4-12)아릴, 헤테로(C1-10)아릴, (C9-12)바이사이클로아릴 및 헤테로(C4-12)바이사이클로아릴로 이루어진 군 중에서 선택되는데, 이들 각각은 치환되거나 치환되지 않은 것이다.